- Home
- NMCO vs PHAR Comparison
NMCO vs PHAR Comparison
Compare NMCO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- PHAR
- Stock Information
- Founded
- NMCO 2019
- PHAR 1988
- Country
- NMCO United States
- PHAR Netherlands
- Employees
- NMCO N/A
- PHAR N/A
- Industry
- NMCO Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- PHAR Health Care
- Exchange
- NMCO Nasdaq
- PHAR Nasdaq
- Market Cap
- NMCO 577.1M
- PHAR 718.1M
- IPO Year
- NMCO N/A
- PHAR N/A
- Fundamental
- Price
- NMCO $10.78
- PHAR $10.27
- Analyst Decision
- NMCO
- PHAR Strong Buy
- Analyst Count
- NMCO 0
- PHAR 3
- Target Price
- NMCO N/A
- PHAR $30.00
- AVG Volume (30 Days)
- NMCO 207.6K
- PHAR 4.3K
- Earning Date
- NMCO 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- NMCO 5.43%
- PHAR N/A
- EPS Growth
- NMCO N/A
- PHAR N/A
- EPS
- NMCO N/A
- PHAR N/A
- Revenue
- NMCO N/A
- PHAR $320,708,000.00
- Revenue This Year
- NMCO N/A
- PHAR $13.31
- Revenue Next Year
- NMCO N/A
- PHAR $7.68
- P/E Ratio
- NMCO N/A
- PHAR N/A
- Revenue Growth
- NMCO N/A
- PHAR 24.13
- 52 Week Low
- NMCO $8.52
- PHAR $6.65
- 52 Week High
- NMCO $11.64
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- NMCO 65.70
- PHAR 48.21
- Support Level
- NMCO $10.76
- PHAR $10.46
- Resistance Level
- NMCO $10.91
- PHAR $11.49
- Average True Range (ATR)
- NMCO 0.13
- PHAR 0.37
- MACD
- NMCO 0.03
- PHAR -0.12
- Stochastic Oscillator
- NMCO 76.79
- PHAR 27.62
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.